On Monday, Mattel, Inc. (NASDAQ:MAT)’s shares declined -0.02% to $25.81.
Mattel, Inc. (MAT) had been a good steward of capital in the past, recent sales declines indicate that the firm’s merchandise was poorly aligned with consumer demand, putting its previous capital-allocation policy and brand equity at risk. Further, a turnover in leadership, underperforming inventory management, volatile currency movements, and lower forecast cash flows could pressure returns on invested capital at least in the near term; we forecast ROICs to fall to 15% in 2015 from more than 30% in 2013. Despite what we perceive to be a temporary destruction in value, Mattel’s brand equity has not been permanently impaired, in our opinion, but the road to redemption could take some time.
New CEO Christopher Sinclair’s background is impressive; he has led companies across the information technology, venture capital, and packaged goods industries. We expected Mattel to seek out a leader with experience across retail, digital (an area in which the firm has seriously lagged), and supply chain, making Sinclair a good fit with his breadth of knowledge and experience.
Mattel, Inc. designs, manufactures, and markets a range of toy products worldwide. The company operates in three segments: North America, International, and American Girl. It offers dolls and accessories, vehicles and play sets, and games and puzzles under the Mattel Girls & Boys brands, counting Barbie, Monster High, Disney Classics, Ever After High, Little Mommy, Polly Pocket, Hot Wheels, Matchbox, CARS, Disney Planes, BOOMco, Radica, Toy Story, Max Steel, WWE Wrestling, and Batman.
Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)’s shares dropped -18.53% to $3.21.
Actinium Pharmaceuticals Inc (ATNM) sponsored the 9th Symposium on Targeted Alpha Therapy, held in Warsaw, Poland on May 19-21. Symposium organizers comprised of the Institute for Transuranium Elements of the European Commission and other sponsors comprise the U.S. Department of Energy. The latest developments in alpha emitter therapy were talk about, such as clinical experiences with alpha emitters counting actinium.
Dr. Joseph G. Jurcic, Professor of Medicine at Columbia University Medical Center and Chairman of Actinium’s Clinical Advisory Board, presented “Targeted Alpha-Particle Therapy with Actinium-225 (225Ac)-Lintuzumab for Acute Myeloid Leukemia (AML) Alone and in Combination with Low-Dose Cytarabine (LDAC)”. A review of the target (CD33), the antibody (Lintuzumab, also called HuM195) and the payload (actinium-225, a potent alpha-emitter) was given. He also offered a clinical update on the ongoing Phase I/II study of Actimab-A, the Company’s alpha-emitting radiolabeled antibody, being developed for older patients with newly diagnosed acute myeloid leukemia (AML).
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
At the end of Monday’s trade, DIRECTV (NASDAQ:DTV)‘s shares dipped -0.10% to $90.95.
DIRECTV (DTV) DIRECTV is assisting parents breathe a sigh of relief with the launch of its new DIRECTV Kids App, an easy-to-use and safe online environment that offers DIRECTV customers age-appropriate content anywhere, anytime – at no extra charge. The new DIRECTV Kids App, designed for children ages 5-10, offers hundreds of popular children’s shows and kid-friendly movies, accessible to watch instantly from Nickelodeon, Cartoon Network, HBO, STARZ, Sprout and more, based on the customer’s DIRECTV programming package.
DIRECTV will also use its long-standing relationship with Common Sense Media, to incorporate age-based ratings and reviews through the App. Common Sense Media is a not-for-profit organization dedicated to providing independent, trustworthy information and education to kids, parents and educators, so they can be better equipped to succeed in a world of media and technology.
DIRECTV, a digital television entertainment company, engages in the direct-to-home (DTH) business in the United States and Latin America. It acquires, promotes, sells, and distributes digital entertainment programming primarily through satellite to residential and commercial subscribers.
Autodesk, Inc. (NASDAQ:ADSK), ended its Monday’s trading session with 0.44% gain, and closed at $54.39.
Autodesk, Inc. (ADSK) declared that it has initiated the U.S. federal government compliance process for cloud products and services known as the Federal Risk and Authorization Administration Program (FedRAMP).
FedRAMP compliance will allow Autodesk to better serve government agencies that require the certification to use cloud offerings such as Autodesk A360 and Autodesk BIM 360 Glue to drive innovation, agility and efficiencies. Autodesk achieved FedRAMP “in process” status by partnering with the United States Army Corps of Engineers (USACE) and will continue to work toward FedRAMP security requirements through USACE. Autodesk has worked closely with the federal agency for the last decade, assisting to ensure that industry standards, such as Building Information Modeling (BIM), are easily and effectively used throughout the Corps’ engineering programs.
Autodesk, Inc. operates as a design software and services company worldwide. The companys Architecture, Engineering and Construction segment offers Autodesk Building Design Suites to manage various phases of design and construction; Autodesk Revit products that provide model-based design and documentation systems; Autodesk Infrastructure Design Suites; AutoCAD Civil 3D products that offer a surveying, design, analysis, and documentation solution; and AutoCAD Map 3D software, which offers direct access to data needed for infrastructure planning, design, and administration.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
